"Bear I am getting really confused here.I understand the trial failure.Are we to understand that the great data that DM highlighted on Renal was overstated.It seemed to me that after DM presentation the value of RVX looked to be Renal."

What are you confused about? The trial failed to achieve statistical significance for its primary endpoint despite everything trending in the right direction. At the same time, subgroup analyses show huge MACE reduction for CKD patients, low LDL-C patients and those on SGLT2 inhibitors. CHF observations are great, but were not part of the primary endpoint. Positive subgroup analyses and secondary endpoints don't reverse the point that BETonMACE failed the primary endpoint for total population.

So what are you confused about?

For me, my only confusion is why not a peep on eGFR changes in the CKD subgroup.

BDAZ